Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

Showing products 1–24 of 37. More products

SUMATRIPTAN SUCCINATE

Form:

24 of 24 products shown

All strengths: Off-Formulary Interchangeable, not an ODB benefit; same patient cost rules

Shared coverage and patient cost rules
StatusOff-Formulary Interchangeable, not an ODB benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (N02CC) — coverage varies; not interchangeable

  • Almotriptan (Axert): not a benefit
  • Eletriptan (Relpax): not a benefit
  • Frovatriptan (Frova): not a benefit
  • Naratriptan (Amerge): not a benefit
  • Rizatriptan (Maxalt RPD): not a benefit
  • Zolmitriptan (Zomig Rapimelt): not a benefit

1 more in the class list below

Imitrex · DIN 02212188 · 6mg/0.5mL · injection, pre-filled syringe 0.5mL Pk

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access criteria on record are for Brand(s): Imitrex; DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Almotriptan Brand(s): Axert DOSAGE FORM/ STRENGTH: 6 mg, 12.5mg tablet Naratriptan Brand(s): Amerge DOSAGE FORM/ STRENGTH: 1 mg, 2.5 mg tablet Rizatriptan Brand(s): Maxalt, Maxalt RPD DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer Sumatriptan Brand(s): Imitrex DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and where the following information is provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. Duration of Approval: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. 217 Sumatriptan Brand(s): Imitrex Injection DOSAGE FORM/ STRENGTH: 12 mg/mL subcutaneous injection Brand(s): Imitrex Nasal Spray DOSAGE FORM/ STRENGTH: 5 mg/dose and 20 mg/dose nasal spray For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and has documented intolerance* to an oral triptan. The following information must also be provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. * The nature of intolerance or why oral sumatriptan cannot be used must be specified. Duration of Approval 5 years Renewal requests for sumatriptan may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 217, record 127, corpus 2025-01-01; name match only, not an eligibility decision
1 brand, same coverage
Imitrex · DIN 02212188 Manufacturer: Glaxo Wellcome Inc.; listing date 2013-04-30 Health Canada: Marketed since 2003-08-11 · brand IMITREX · ATC N02CC01 SUMATRIPTAN · form Solution · route Subcutaneous · ingredients SUMATRIPTAN (SUMATRIPTAN SUCCINATE) 6 MG/0.5ML · company Glaxosmithkline inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $42.4650 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43078 · Verify on the e-Formulary ↗ (DIN 02212188)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02212188). DIN 02212188: Imitrex Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200007; group id 545; item number 1470; lccId None; manufacturer id GLW Source form: Inj Sol-Pref Syr 0.5mL Pk; strength: 6mg/0.5mL Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $55.3600; ministry $42.4650 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02212188 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43078
Interchangeable products
Taro-Sumatriptan · DIN 02361698 · $42.4650
Shortage status: resolved shortage (ended 2024-04-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02212188
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Taro-Sumatriptan · DIN 02361698 · 6mg/0.5mL · injection, pre-filled syringe 0.5mL Pk

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access criteria on record are for Brand(s): Imitrex; DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Almotriptan Brand(s): Axert DOSAGE FORM/ STRENGTH: 6 mg, 12.5mg tablet Naratriptan Brand(s): Amerge DOSAGE FORM/ STRENGTH: 1 mg, 2.5 mg tablet Rizatriptan Brand(s): Maxalt, Maxalt RPD DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer Sumatriptan Brand(s): Imitrex DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and where the following information is provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. Duration of Approval: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. 217 Sumatriptan Brand(s): Imitrex Injection DOSAGE FORM/ STRENGTH: 12 mg/mL subcutaneous injection Brand(s): Imitrex Nasal Spray DOSAGE FORM/ STRENGTH: 5 mg/dose and 20 mg/dose nasal spray For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and has documented intolerance* to an oral triptan. The following information must also be provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. * The nature of intolerance or why oral sumatriptan cannot be used must be specified. Duration of Approval 5 years Renewal requests for sumatriptan may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 217, record 127, corpus 2025-01-01; name match only, not an eligibility decision
1 brand, same coverage
Taro-Sumatriptan · DIN 02361698 Manufacturer: Taro Pharmaceuticals Inc.; listing date 2013-04-30 Health Canada: Marketed since 2013-09-20 · brand TARO-SUMATRIPTAN · ATC N02CC01 SUMATRIPTAN · form Solution · route Subcutaneous · ingredients SUMATRIPTAN (SUMATRIPTAN SUCCINATE) 6 MG/0.5ML · company Taro pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Taro-Sumatriptan: Formulary list price $42.4650/unit (unit not stated in source; not the patient's cost)

Ministry pays: $42.4650 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84675 · Verify on the e-Formulary ↗ (DIN 02361698)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02361698). DIN 02361698: Taro-Sumatriptan Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200007; group id 545; item number 1470; lccId None; manufacturer id TAR Source form: Inj Sol-Pref Syr 0.5mL Pk; strength: 6mg/0.5mL Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $42.4650; ministry $42.4650 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02361698 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84675
Interchangeable products
Imitrex · DIN 02212188 · $42.4650
Shortage status: resolved shortage (ended 2023-01-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02361698
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Sumatriptan DF · DIN 02545292 · 25mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access criteria on record are for Brand(s): Imitrex; DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Almotriptan Brand(s): Axert DOSAGE FORM/ STRENGTH: 6 mg, 12.5mg tablet Naratriptan Brand(s): Amerge DOSAGE FORM/ STRENGTH: 1 mg, 2.5 mg tablet Rizatriptan Brand(s): Maxalt, Maxalt RPD DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer Sumatriptan Brand(s): Imitrex DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and where the following information is provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. Duration of Approval: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. 217 Sumatriptan Brand(s): Imitrex Injection DOSAGE FORM/ STRENGTH: 12 mg/mL subcutaneous injection Brand(s): Imitrex Nasal Spray DOSAGE FORM/ STRENGTH: 5 mg/dose and 20 mg/dose nasal spray For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and has documented intolerance* to an oral triptan. The following information must also be provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. * The nature of intolerance or why oral sumatriptan cannot be used must be specified. Duration of Approval 5 years Renewal requests for sumatriptan may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 217, record 127, corpus 2025-01-01; name match only, not an eligibility decision
1 brand, same coverage
Jamp Sumatriptan DF · DIN 02545292 Manufacturer: Jamp Pharma Corporation; listing date 2025-01-31 Health Canada: Marketed since 2024-09-30 · brand JAMP SUMATRIPTAN DF · ATC N02CC01 SUMATRIPTAN · form Tablet · route Oral · ingredients SUMATRIPTAN (SUMATRIPTAN SUCCINATE) 25 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103407 · Verify on the e-Formulary ↗ (DIN 02545292)

Source record
DIN 02545292: Jamp Sumatriptan DF Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 289200026; group id 545; item number 1472; lccId None; manufacturer id JPC Source form: Tab; strength: 25mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $8.9900; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02545292 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103407
Interchangeable products
Imitrex DF · DIN 02239738 · not recorded Teva-Sumatriptan DF · DIN 02286815 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02545292
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mylan-Sumatriptan · DIN 02268906 · 25mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access criteria on record are for Brand(s): Imitrex; DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Almotriptan Brand(s): Axert DOSAGE FORM/ STRENGTH: 6 mg, 12.5mg tablet Naratriptan Brand(s): Amerge DOSAGE FORM/ STRENGTH: 1 mg, 2.5 mg tablet Rizatriptan Brand(s): Maxalt, Maxalt RPD DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer Sumatriptan Brand(s): Imitrex DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and where the following information is provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. Duration of Approval: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. 217 Sumatriptan Brand(s): Imitrex Injection DOSAGE FORM/ STRENGTH: 12 mg/mL subcutaneous injection Brand(s): Imitrex Nasal Spray DOSAGE FORM/ STRENGTH: 5 mg/dose and 20 mg/dose nasal spray For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and has documented intolerance* to an oral triptan. The following information must also be provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. * The nature of intolerance or why oral sumatriptan cannot be used must be specified. Duration of Approval 5 years Renewal requests for sumatriptan may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 217, record 127, corpus 2025-01-01; name match only, not an eligibility decision
1 brand, same coverage
Mylan-Sumatriptan · DIN 02268906 Manufacturer: Mylan Pharmaceuticals ULC; listing date 2007-06-06 Health Canada: Marketed since 2010-06-30 · brand MYLAN-SUMATRIPTAN · ATC N02CC01 SUMATRIPTAN · form Tablet · route Oral · ingredients SUMATRIPTAN (SUMATRIPTAN SUCCINATE) 25 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Mylan-Sumatriptan: Formulary list price $8.9900/unit (unit not stated in source; not the patient's cost)

Ministry pays: $8.9900 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75430 · Verify on the e-Formulary ↗ (DIN 02268906)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02268906). DIN 02268906: Mylan-Sumatriptan Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200012; group id 545; item number 1471; lccId None; manufacturer id MYL Source form: Tab; strength: 25mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $8.9900; ministry $8.9900 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02268906 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75430
Interchangeable products
Co Sumatriptan · DIN 02257882 · $8.9900 Imitrex · DIN 09857299 · not recorded PMS-Sumatriptan · DIN 02256428 · $8.9900
Shortage status: resolved shortage (ended 2023-10-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02268906
Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Sumatriptan · DIN 02256428 · 25mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access criteria on record are for Brand(s): Imitrex; DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Almotriptan Brand(s): Axert DOSAGE FORM/ STRENGTH: 6 mg, 12.5mg tablet Naratriptan Brand(s): Amerge DOSAGE FORM/ STRENGTH: 1 mg, 2.5 mg tablet Rizatriptan Brand(s): Maxalt, Maxalt RPD DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer Sumatriptan Brand(s): Imitrex DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and where the following information is provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. Duration of Approval: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. 217 Sumatriptan Brand(s): Imitrex Injection DOSAGE FORM/ STRENGTH: 12 mg/mL subcutaneous injection Brand(s): Imitrex Nasal Spray DOSAGE FORM/ STRENGTH: 5 mg/dose and 20 mg/dose nasal spray For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and has documented intolerance* to an oral triptan. The following information must also be provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. * The nature of intolerance or why oral sumatriptan cannot be used must be specified. Duration of Approval 5 years Renewal requests for sumatriptan may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 217, record 127, corpus 2025-01-01; name match only, not an eligibility decision
1 brand, same coverage
PMS-Sumatriptan · DIN 02256428 Manufacturer: Pharmascience Inc.; listing date 2007-06-06 Health Canada: Marketed since 2005-08-24 · brand PMS-SUMATRIPTAN · ATC N02CC01 SUMATRIPTAN · form Tablet · route Oral · ingredients SUMATRIPTAN (SUMATRIPTAN SUCCINATE) 25 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

PMS-Sumatriptan: Formulary list price $8.9900/unit (unit not stated in source; not the patient's cost)

Ministry pays: $8.9900 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74163 · Verify on the e-Formulary ↗ (DIN 02256428)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02256428). DIN 02256428: PMS-Sumatriptan Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200012; group id 545; item number 1471; lccId None; manufacturer id PMS Source form: Tab; strength: 25mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $8.9900; ministry $8.9900 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02256428 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74163
Interchangeable products
Co Sumatriptan · DIN 02257882 · $8.9900 Imitrex · DIN 09857299 · not recorded Mylan-Sumatriptan · DIN 02268906 · $8.9900
Shortage status: resolved shortage (ended 2025-05-08); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02256428
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Sumatriptan DF · DIN 02286815 · 25mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access criteria on record are for Brand(s): Imitrex; DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Almotriptan Brand(s): Axert DOSAGE FORM/ STRENGTH: 6 mg, 12.5mg tablet Naratriptan Brand(s): Amerge DOSAGE FORM/ STRENGTH: 1 mg, 2.5 mg tablet Rizatriptan Brand(s): Maxalt, Maxalt RPD DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer Sumatriptan Brand(s): Imitrex DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and where the following information is provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. Duration of Approval: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. 217 Sumatriptan Brand(s): Imitrex Injection DOSAGE FORM/ STRENGTH: 12 mg/mL subcutaneous injection Brand(s): Imitrex Nasal Spray DOSAGE FORM/ STRENGTH: 5 mg/dose and 20 mg/dose nasal spray For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and has documented intolerance* to an oral triptan. The following information must also be provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. * The nature of intolerance or why oral sumatriptan cannot be used must be specified. Duration of Approval 5 years Renewal requests for sumatriptan may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 217, record 127, corpus 2025-01-01; name match only, not an eligibility decision
1 brand, same coverage
Teva-Sumatriptan DF · DIN 02286815 Manufacturer: Teva Canada Limited; listing date 2007-06-06 Health Canada: Marketed since 2011-06-29 · brand TEVA-SUMATRIPTAN DF · ATC N02CC01 SUMATRIPTAN · form Tablet · route Oral · ingredients SUMATRIPTAN (SUMATRIPTAN SUCCINATE) 25 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77227 · Verify on the e-Formulary ↗ (DIN 02286815)

Source record
DIN 02286815: Teva-Sumatriptan DF Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 289200026; group id 545; item number 1472; lccId None; manufacturer id TEV Source form: Tab; strength: 25mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $8.9900; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02286815 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77227
Interchangeable products
Imitrex DF · DIN 02239738 · not recorded Jamp Sumatriptan DF · DIN 02545292 · not recorded
Shortage status: resolved shortage (ended 2025-10-14); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02286815
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Sumatriptan · DIN 02268388 · 50mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access criteria on record are for Brand(s): Imitrex; DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Almotriptan Brand(s): Axert DOSAGE FORM/ STRENGTH: 6 mg, 12.5mg tablet Naratriptan Brand(s): Amerge DOSAGE FORM/ STRENGTH: 1 mg, 2.5 mg tablet Rizatriptan Brand(s): Maxalt, Maxalt RPD DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer Sumatriptan Brand(s): Imitrex DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and where the following information is provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. Duration of Approval: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. 217 Sumatriptan Brand(s): Imitrex Injection DOSAGE FORM/ STRENGTH: 12 mg/mL subcutaneous injection Brand(s): Imitrex Nasal Spray DOSAGE FORM/ STRENGTH: 5 mg/dose and 20 mg/dose nasal spray For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and has documented intolerance* to an oral triptan. The following information must also be provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. * The nature of intolerance or why oral sumatriptan cannot be used must be specified. Duration of Approval 5 years Renewal requests for sumatriptan may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 217, record 127, corpus 2025-01-01; name match only, not an eligibility decision
1 brand, same coverage
Apo-Sumatriptan · DIN 02268388 Manufacturer: Apotex Inc.; listing date 2007-06-06 Health Canada: Marketed since 2005-08-24 · brand APO-SUMATRIPTAN · ATC N02CC01 SUMATRIPTAN · form Tablet · route Oral · ingredients SUMATRIPTAN (SUMATRIPTAN SUCCINATE) 50 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Sumatriptan: Formulary list price $9.0650/unit (unit not stated in source; not the patient's cost)

Ministry pays: $9.0650 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75377 · Verify on the e-Formulary ↗ (DIN 02268388)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02268388). DIN 02268388: Apo-Sumatriptan Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200009; group id 545; item number 1473; lccId None; manufacturer id APX Source form: Tab; strength: 50mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $9.0650; ministry $9.0650 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02268388 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75377
Interchangeable products
Co Sumatriptan · DIN 02257890 · $9.0650 Imitrex · DIN 02163764 · not recorded Jamp Sumatriptan · DIN 02545357 · $9.0650 Mylan-Sumatriptan · DIN 02268914 · $9.0650 PMS-Sumatriptan · DIN 02256436 · $9.0650 Ratio-Sumatriptan · DIN 02271583 · $9.0650 Sandoz Sumatriptan · DIN 02263025 · $9.0650 Sumatriptan · DIN 02286521 · $9.0650 Sumatriptan · DIN 02546035 · $9.0650
Shortage status: resolved shortage (ended 2024-04-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02268388
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Sumatriptan · DIN 02545357 · 50mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access criteria on record are for Brand(s): Imitrex; DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Almotriptan Brand(s): Axert DOSAGE FORM/ STRENGTH: 6 mg, 12.5mg tablet Naratriptan Brand(s): Amerge DOSAGE FORM/ STRENGTH: 1 mg, 2.5 mg tablet Rizatriptan Brand(s): Maxalt, Maxalt RPD DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer Sumatriptan Brand(s): Imitrex DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and where the following information is provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. Duration of Approval: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. 217 Sumatriptan Brand(s): Imitrex Injection DOSAGE FORM/ STRENGTH: 12 mg/mL subcutaneous injection Brand(s): Imitrex Nasal Spray DOSAGE FORM/ STRENGTH: 5 mg/dose and 20 mg/dose nasal spray For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and has documented intolerance* to an oral triptan. The following information must also be provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. * The nature of intolerance or why oral sumatriptan cannot be used must be specified. Duration of Approval 5 years Renewal requests for sumatriptan may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 217, record 127, corpus 2025-01-01; name match only, not an eligibility decision
1 brand, same coverage
Jamp Sumatriptan · DIN 02545357 Manufacturer: Jamp Pharma Corporation; listing date 2024-12-30 Health Canada: Marketed since 2024-11-01 · brand JAMP SUMATRIPTAN · ATC N02CC01 SUMATRIPTAN · form Tablet · route Oral · ingredients SUMATRIPTAN (SUMATRIPTAN SUCCINATE) 50 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp Sumatriptan: Formulary list price $9.0650/unit (unit not stated in source; not the patient's cost)

Ministry pays: $9.0650 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103413 · Verify on the e-Formulary ↗ (DIN 02545357)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02545357). DIN 02545357: Jamp Sumatriptan Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200009; group id 545; item number 1473; lccId None; manufacturer id JPC Source form: Tab; strength: 50mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $9.0650; ministry $9.0650 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02545357 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103413
Interchangeable products
Apo-Sumatriptan · DIN 02268388 · $9.0650 Co Sumatriptan · DIN 02257890 · $9.0650 Imitrex · DIN 02163764 · not recorded Mylan-Sumatriptan · DIN 02268914 · $9.0650 PMS-Sumatriptan · DIN 02256436 · $9.0650 Ratio-Sumatriptan · DIN 02271583 · $9.0650 Sandoz Sumatriptan · DIN 02263025 · $9.0650 Sumatriptan · DIN 02286521 · $9.0650 Sumatriptan · DIN 02546035 · $9.0650
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02545357
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Sumatriptan DF · DIN 02545306 · 50mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access criteria on record are for Brand(s): Imitrex; DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Almotriptan Brand(s): Axert DOSAGE FORM/ STRENGTH: 6 mg, 12.5mg tablet Naratriptan Brand(s): Amerge DOSAGE FORM/ STRENGTH: 1 mg, 2.5 mg tablet Rizatriptan Brand(s): Maxalt, Maxalt RPD DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer Sumatriptan Brand(s): Imitrex DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and where the following information is provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. Duration of Approval: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. 217 Sumatriptan Brand(s): Imitrex Injection DOSAGE FORM/ STRENGTH: 12 mg/mL subcutaneous injection Brand(s): Imitrex Nasal Spray DOSAGE FORM/ STRENGTH: 5 mg/dose and 20 mg/dose nasal spray For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and has documented intolerance* to an oral triptan. The following information must also be provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. * The nature of intolerance or why oral sumatriptan cannot be used must be specified. Duration of Approval 5 years Renewal requests for sumatriptan may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 217, record 127, corpus 2025-01-01; name match only, not an eligibility decision
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Sumatriptan DF · DIN 02545306 Manufacturer: Jamp Pharma Corporation; listing date 2025-01-31 Health Canada: Marketed since 2024-09-30 · brand JAMP SUMATRIPTAN DF · ATC N02CC01 SUMATRIPTAN · form Tablet · route Oral · ingredients SUMATRIPTAN (SUMATRIPTAN SUCCINATE) 50 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp Sumatriptan DF: Formulary list price $9.0650/unit (unit not stated in source; not the patient's cost)

Ministry pays: $9.0650 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103408 · Verify on the e-Formulary ↗ (DIN 02545306)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02545306). DIN 02545306: Jamp Sumatriptan DF Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200027; group id 545; item number 1474; lccId None; manufacturer id JPC Source form: Tab; strength: 50mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $9.0650; ministry $9.0650 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02545306 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103408
Interchangeable products
Imitrex DF · DIN 02212153 · $9.0650 Sumatriptan DF · DIN 02385570 · $9.0650 Teva-Sumatriptan DF · DIN 02286823 · $9.0650
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02545306
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mylan-Sumatriptan · DIN 02268914 · 50mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access criteria on record are for Brand(s): Imitrex; DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Almotriptan Brand(s): Axert DOSAGE FORM/ STRENGTH: 6 mg, 12.5mg tablet Naratriptan Brand(s): Amerge DOSAGE FORM/ STRENGTH: 1 mg, 2.5 mg tablet Rizatriptan Brand(s): Maxalt, Maxalt RPD DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer Sumatriptan Brand(s): Imitrex DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and where the following information is provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. Duration of Approval: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. 217 Sumatriptan Brand(s): Imitrex Injection DOSAGE FORM/ STRENGTH: 12 mg/mL subcutaneous injection Brand(s): Imitrex Nasal Spray DOSAGE FORM/ STRENGTH: 5 mg/dose and 20 mg/dose nasal spray For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and has documented intolerance* to an oral triptan. The following information must also be provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. * The nature of intolerance or why oral sumatriptan cannot be used must be specified. Duration of Approval 5 years Renewal requests for sumatriptan may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 217, record 127, corpus 2025-01-01; name match only, not an eligibility decision
1 brand, same coverage
Mylan-Sumatriptan · DIN 02268914 Manufacturer: Mylan Pharmaceuticals ULC; listing date 2007-06-06 Health Canada: Marketed since 2010-02-08 · brand MYLAN-SUMATRIPTAN · ATC N02CC01 SUMATRIPTAN · form Tablet · route Oral · ingredients SUMATRIPTAN (SUMATRIPTAN SUCCINATE) 50 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Mylan-Sumatriptan: Formulary list price $9.0650/unit (unit not stated in source; not the patient's cost)

Ministry pays: $9.0650 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75431 · Verify on the e-Formulary ↗ (DIN 02268914)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02268914). DIN 02268914: Mylan-Sumatriptan Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200009; group id 545; item number 1473; lccId None; manufacturer id MYL Source form: Tab; strength: 50mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $9.0650; ministry $9.0650 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02268914 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75431
Interchangeable products
Apo-Sumatriptan · DIN 02268388 · $9.0650 Co Sumatriptan · DIN 02257890 · $9.0650 Imitrex · DIN 02163764 · not recorded Jamp Sumatriptan · DIN 02545357 · $9.0650 PMS-Sumatriptan · DIN 02256436 · $9.0650 Ratio-Sumatriptan · DIN 02271583 · $9.0650 Sandoz Sumatriptan · DIN 02263025 · $9.0650 Sumatriptan · DIN 02286521 · $9.0650 Sumatriptan · DIN 02546035 · $9.0650
Shortage status: anticipated shortage (last updated 2026-09-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02268914
Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Sumatriptan · DIN 02256436 · 50mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access criteria on record are for Brand(s): Imitrex; DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Almotriptan Brand(s): Axert DOSAGE FORM/ STRENGTH: 6 mg, 12.5mg tablet Naratriptan Brand(s): Amerge DOSAGE FORM/ STRENGTH: 1 mg, 2.5 mg tablet Rizatriptan Brand(s): Maxalt, Maxalt RPD DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer Sumatriptan Brand(s): Imitrex DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and where the following information is provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. Duration of Approval: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. 217 Sumatriptan Brand(s): Imitrex Injection DOSAGE FORM/ STRENGTH: 12 mg/mL subcutaneous injection Brand(s): Imitrex Nasal Spray DOSAGE FORM/ STRENGTH: 5 mg/dose and 20 mg/dose nasal spray For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and has documented intolerance* to an oral triptan. The following information must also be provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. * The nature of intolerance or why oral sumatriptan cannot be used must be specified. Duration of Approval 5 years Renewal requests for sumatriptan may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 217, record 127, corpus 2025-01-01; name match only, not an eligibility decision
1 brand, same coverage
PMS-Sumatriptan · DIN 02256436 Manufacturer: Pharmascience Inc.; listing date 2007-06-06 Health Canada: Marketed since 2005-08-24 · brand PMS-SUMATRIPTAN · ATC N02CC01 SUMATRIPTAN · form Tablet · route Oral · ingredients SUMATRIPTAN (SUMATRIPTAN SUCCINATE) 50 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

PMS-Sumatriptan: Formulary list price $9.0650/unit (unit not stated in source; not the patient's cost)

Ministry pays: $9.0650 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74164 · Verify on the e-Formulary ↗ (DIN 02256436)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02256436). DIN 02256436: PMS-Sumatriptan Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200009; group id 545; item number 1473; lccId None; manufacturer id PMS Source form: Tab; strength: 50mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $9.0650; ministry $9.0650 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02256436 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74164
Interchangeable products
Apo-Sumatriptan · DIN 02268388 · $9.0650 Co Sumatriptan · DIN 02257890 · $9.0650 Imitrex · DIN 02163764 · not recorded Jamp Sumatriptan · DIN 02545357 · $9.0650 Mylan-Sumatriptan · DIN 02268914 · $9.0650 Ratio-Sumatriptan · DIN 02271583 · $9.0650 Sandoz Sumatriptan · DIN 02263025 · $9.0650 Sumatriptan · DIN 02286521 · $9.0650 Sumatriptan · DIN 02546035 · $9.0650
Shortage status: resolved shortage (ended 2024-07-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02256436
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sumatriptan · DIN 02286521 · 50mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access criteria on record are for Brand(s): Imitrex; DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Almotriptan Brand(s): Axert DOSAGE FORM/ STRENGTH: 6 mg, 12.5mg tablet Naratriptan Brand(s): Amerge DOSAGE FORM/ STRENGTH: 1 mg, 2.5 mg tablet Rizatriptan Brand(s): Maxalt, Maxalt RPD DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer Sumatriptan Brand(s): Imitrex DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and where the following information is provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. Duration of Approval: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. 217 Sumatriptan Brand(s): Imitrex Injection DOSAGE FORM/ STRENGTH: 12 mg/mL subcutaneous injection Brand(s): Imitrex Nasal Spray DOSAGE FORM/ STRENGTH: 5 mg/dose and 20 mg/dose nasal spray For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and has documented intolerance* to an oral triptan. The following information must also be provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. * The nature of intolerance or why oral sumatriptan cannot be used must be specified. Duration of Approval 5 years Renewal requests for sumatriptan may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 217, record 127, corpus 2025-01-01; name match only, not an eligibility decision
1 brand, same coverage
Sumatriptan · DIN 02286521 Manufacturer: Sanis Health Inc.; listing date 2011-08-04 Health Canada: Marketed since 2010-04-05 · brand SUMATRIPTAN · ATC N02CC01 SUMATRIPTAN · form Tablet · route Oral · ingredients SUMATRIPTAN (SUMATRIPTAN SUCCINATE) 50 MG · company Sanis health inc · schedule Prescription
Check this DIN again · Health Canada product record

Sumatriptan: Formulary list price $9.0650/unit (unit not stated in source; not the patient's cost)

Ministry pays: $9.0650 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77198 · Verify on the e-Formulary ↗ (DIN 02286521)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02286521). DIN 02286521: Sumatriptan Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200009; group id 545; item number 1473; lccId None; manufacturer id SAI Source form: Tab; strength: 50mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $9.0650; ministry $9.0650 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02286521 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77198
Interchangeable products
Apo-Sumatriptan · DIN 02268388 · $9.0650 Co Sumatriptan · DIN 02257890 · $9.0650 Imitrex · DIN 02163764 · not recorded Jamp Sumatriptan · DIN 02545357 · $9.0650 Mylan-Sumatriptan · DIN 02268914 · $9.0650 PMS-Sumatriptan · DIN 02256436 · $9.0650 Ratio-Sumatriptan · DIN 02271583 · $9.0650 Sandoz Sumatriptan · DIN 02263025 · $9.0650 Sumatriptan · DIN 02546035 · $9.0650
Shortage status: resolved shortage (ended 2026-02-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02286521
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sumatriptan · DIN 02546035 · 50mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access criteria on record are for Brand(s): Imitrex; DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Almotriptan Brand(s): Axert DOSAGE FORM/ STRENGTH: 6 mg, 12.5mg tablet Naratriptan Brand(s): Amerge DOSAGE FORM/ STRENGTH: 1 mg, 2.5 mg tablet Rizatriptan Brand(s): Maxalt, Maxalt RPD DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer Sumatriptan Brand(s): Imitrex DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and where the following information is provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. Duration of Approval: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. 217 Sumatriptan Brand(s): Imitrex Injection DOSAGE FORM/ STRENGTH: 12 mg/mL subcutaneous injection Brand(s): Imitrex Nasal Spray DOSAGE FORM/ STRENGTH: 5 mg/dose and 20 mg/dose nasal spray For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and has documented intolerance* to an oral triptan. The following information must also be provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. * The nature of intolerance or why oral sumatriptan cannot be used must be specified. Duration of Approval 5 years Renewal requests for sumatriptan may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 217, record 127, corpus 2025-01-01; name match only, not an eligibility decision
1 brand, same coverage
Sumatriptan · DIN 02546035 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2024-05-31 Health Canada: Marketed since 2024-04-29 · brand SUMATRIPTAN · ATC N02CC01 SUMATRIPTAN · form Tablet · route Oral · ingredients SUMATRIPTAN (SUMATRIPTAN SUCCINATE) 50 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Sumatriptan: Formulary list price $9.0650/unit (unit not stated in source; not the patient's cost)

Ministry pays: $9.0650 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103476 · Verify on the e-Formulary ↗ (DIN 02546035)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02546035). DIN 02546035: Sumatriptan Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200009; group id 545; item number 1473; lccId None; manufacturer id SIV Source form: Tab; strength: 50mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $9.0650; ministry $9.0650 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02546035 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103476
Interchangeable products
Apo-Sumatriptan · DIN 02268388 · $9.0650 Co Sumatriptan · DIN 02257890 · $9.0650 Imitrex · DIN 02163764 · not recorded Jamp Sumatriptan · DIN 02545357 · $9.0650 Mylan-Sumatriptan · DIN 02268914 · $9.0650 PMS-Sumatriptan · DIN 02256436 · $9.0650 Ratio-Sumatriptan · DIN 02271583 · $9.0650 Sandoz Sumatriptan · DIN 02263025 · $9.0650 Sumatriptan · DIN 02286521 · $9.0650
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02546035
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sumatriptan DF · DIN 02385570 · 50mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access criteria on record are for Brand(s): Imitrex; DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Almotriptan Brand(s): Axert DOSAGE FORM/ STRENGTH: 6 mg, 12.5mg tablet Naratriptan Brand(s): Amerge DOSAGE FORM/ STRENGTH: 1 mg, 2.5 mg tablet Rizatriptan Brand(s): Maxalt, Maxalt RPD DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer Sumatriptan Brand(s): Imitrex DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and where the following information is provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. Duration of Approval: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. 217 Sumatriptan Brand(s): Imitrex Injection DOSAGE FORM/ STRENGTH: 12 mg/mL subcutaneous injection Brand(s): Imitrex Nasal Spray DOSAGE FORM/ STRENGTH: 5 mg/dose and 20 mg/dose nasal spray For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and has documented intolerance* to an oral triptan. The following information must also be provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. * The nature of intolerance or why oral sumatriptan cannot be used must be specified. Duration of Approval 5 years Renewal requests for sumatriptan may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 217, record 127, corpus 2025-01-01; name match only, not an eligibility decision
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Sumatriptan DF · DIN 02385570 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-06-30 Health Canada: Marketed since 2023-06-01 · brand SUMATRIPTAN DF · ATC N02CC01 SUMATRIPTAN · form Tablet · route Oral · ingredients SUMATRIPTAN (SUMATRIPTAN SUCCINATE) 50 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Sumatriptan DF: Formulary list price $9.0650/unit (unit not stated in source; not the patient's cost)

Ministry pays: $9.0650 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87118 · Verify on the e-Formulary ↗ (DIN 02385570)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02385570). DIN 02385570: Sumatriptan DF Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200027; group id 545; item number 1474; lccId None; manufacturer id SIV Source form: Tab; strength: 50mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $9.0650; ministry $9.0650 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02385570 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87118
Interchangeable products
Imitrex DF · DIN 02212153 · $9.0650 Jamp Sumatriptan DF · DIN 02545306 · $9.0650 Teva-Sumatriptan DF · DIN 02286823 · $9.0650
Shortage status: resolved shortage (ended 2022-10-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02385570
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Sumatriptan DF · DIN 02286823 · 50mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access criteria on record are for Brand(s): Imitrex; DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Almotriptan Brand(s): Axert DOSAGE FORM/ STRENGTH: 6 mg, 12.5mg tablet Naratriptan Brand(s): Amerge DOSAGE FORM/ STRENGTH: 1 mg, 2.5 mg tablet Rizatriptan Brand(s): Maxalt, Maxalt RPD DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer Sumatriptan Brand(s): Imitrex DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and where the following information is provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. Duration of Approval: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. 217 Sumatriptan Brand(s): Imitrex Injection DOSAGE FORM/ STRENGTH: 12 mg/mL subcutaneous injection Brand(s): Imitrex Nasal Spray DOSAGE FORM/ STRENGTH: 5 mg/dose and 20 mg/dose nasal spray For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and has documented intolerance* to an oral triptan. The following information must also be provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. * The nature of intolerance or why oral sumatriptan cannot be used must be specified. Duration of Approval 5 years Renewal requests for sumatriptan may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 217, record 127, corpus 2025-01-01; name match only, not an eligibility decision
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Teva-Sumatriptan DF · DIN 02286823 Manufacturer: Teva Canada Limited; listing date 2007-06-06 Health Canada: Marketed since 2011-06-29 · brand TEVA-SUMATRIPTAN DF · ATC N02CC01 SUMATRIPTAN · form Tablet · route Oral · ingredients SUMATRIPTAN (SUMATRIPTAN SUCCINATE) 50 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Teva-Sumatriptan DF: Formulary list price $9.0650/unit (unit not stated in source; not the patient's cost)

Ministry pays: $9.0650 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77228 · Verify on the e-Formulary ↗ (DIN 02286823)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02286823). DIN 02286823: Teva-Sumatriptan DF Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200027; group id 545; item number 1474; lccId None; manufacturer id TEV Source form: Tab; strength: 50mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $9.0650; ministry $9.0650 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02286823 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77228
Interchangeable products
Imitrex DF · DIN 02212153 · $9.0650 Jamp Sumatriptan DF · DIN 02545306 · $9.0650 Sumatriptan DF · DIN 02385570 · $9.0650
Shortage status: resolved shortage (ended 2026-03-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02286823
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Sumatriptan · DIN 02268396 · 100mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access criteria on record are for Brand(s): Imitrex; DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Almotriptan Brand(s): Axert DOSAGE FORM/ STRENGTH: 6 mg, 12.5mg tablet Naratriptan Brand(s): Amerge DOSAGE FORM/ STRENGTH: 1 mg, 2.5 mg tablet Rizatriptan Brand(s): Maxalt, Maxalt RPD DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer Sumatriptan Brand(s): Imitrex DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and where the following information is provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. Duration of Approval: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. 217 Sumatriptan Brand(s): Imitrex Injection DOSAGE FORM/ STRENGTH: 12 mg/mL subcutaneous injection Brand(s): Imitrex Nasal Spray DOSAGE FORM/ STRENGTH: 5 mg/dose and 20 mg/dose nasal spray For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and has documented intolerance* to an oral triptan. The following information must also be provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. * The nature of intolerance or why oral sumatriptan cannot be used must be specified. Duration of Approval 5 years Renewal requests for sumatriptan may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 217, record 127, corpus 2025-01-01; name match only, not an eligibility decision
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Sumatriptan · DIN 02268396 Manufacturer: Apotex Inc.; listing date 2007-06-06 Health Canada: Marketed since 2005-08-24 · brand APO-SUMATRIPTAN · ATC N02CC01 SUMATRIPTAN · form Tablet · route Oral · ingredients SUMATRIPTAN (SUMATRIPTAN SUCCINATE) 100 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Sumatriptan: Formulary list price $9.9867/unit (unit not stated in source; not the patient's cost)

Ministry pays: $9.9867 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75378 · Verify on the e-Formulary ↗ (DIN 02268396)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02268396). DIN 02268396: Apo-Sumatriptan Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200006; group id 545; item number 1475; lccId None; manufacturer id APX Source form: Tab; strength: 100mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $9.9867; ministry $9.9867 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02268396 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75378
Interchangeable products
Co Sumatriptan · DIN 02257904 · $9.9867 Imitrex · DIN 01950614 · not recorded Jamp Sumatriptan · DIN 02545365 · $9.9866 Mylan-Sumatriptan · DIN 02268922 · $9.9867 PMS-Sumatriptan · DIN 02256444 · $9.9867 Ratio-Sumatriptan · DIN 02271591 · $9.9867 Sandoz Sumatriptan · DIN 02263033 · $9.9867 Sumatriptan · DIN 02286548 · $9.9867 Sumatriptan · DIN 02546043 · $9.9867
Shortage status: resolved shortage (ended 2024-04-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02268396
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Imitrex DF · DIN 02212161 · 100mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access criteria on record are for Brand(s): Imitrex; DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Almotriptan Brand(s): Axert DOSAGE FORM/ STRENGTH: 6 mg, 12.5mg tablet Naratriptan Brand(s): Amerge DOSAGE FORM/ STRENGTH: 1 mg, 2.5 mg tablet Rizatriptan Brand(s): Maxalt, Maxalt RPD DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer Sumatriptan Brand(s): Imitrex DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and where the following information is provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. Duration of Approval: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. 217 Sumatriptan Brand(s): Imitrex Injection DOSAGE FORM/ STRENGTH: 12 mg/mL subcutaneous injection Brand(s): Imitrex Nasal Spray DOSAGE FORM/ STRENGTH: 5 mg/dose and 20 mg/dose nasal spray For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and has documented intolerance* to an oral triptan. The following information must also be provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. * The nature of intolerance or why oral sumatriptan cannot be used must be specified. Duration of Approval 5 years Renewal requests for sumatriptan may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 217, record 127, corpus 2025-01-01; name match only, not an eligibility decision
Savings card: innoviCares lists Imitrex DF (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Imitrex DF · DIN 02212161 Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 2007-06-06 Health Canada: Marketed since 2004-08-30 · brand IMITREX DF - TAB 100MG · ATC N02CC01 SUMATRIPTAN · form Tablet · route Oral · ingredients SUMATRIPTAN (SUMATRIPTAN SUCCINATE) 100 MG · company Glaxosmithkline inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $9.9866 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43077 · Verify on the e-Formulary ↗ (DIN 02212161)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02212161). DIN 02212161: Imitrex DF Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200028; group id 545; item number 1476; lccId None; manufacturer id GSK Source form: Tab; strength: 100mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $22.2067; ministry $9.9866 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02212161 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43077
Interchangeable products
Jamp Sumatriptan DF · DIN 02545314 · $9.9866 Sumatriptan DF · DIN 02385589 · $9.9866 Teva-Sumatriptan DF · DIN 02286831 · $9.9866
Shortage status: resolved shortage (ended 2022-10-26); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02212161
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Sumatriptan · DIN 02545365 · 100mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access criteria on record are for Brand(s): Imitrex; DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Almotriptan Brand(s): Axert DOSAGE FORM/ STRENGTH: 6 mg, 12.5mg tablet Naratriptan Brand(s): Amerge DOSAGE FORM/ STRENGTH: 1 mg, 2.5 mg tablet Rizatriptan Brand(s): Maxalt, Maxalt RPD DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer Sumatriptan Brand(s): Imitrex DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and where the following information is provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. Duration of Approval: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. 217 Sumatriptan Brand(s): Imitrex Injection DOSAGE FORM/ STRENGTH: 12 mg/mL subcutaneous injection Brand(s): Imitrex Nasal Spray DOSAGE FORM/ STRENGTH: 5 mg/dose and 20 mg/dose nasal spray For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and has documented intolerance* to an oral triptan. The following information must also be provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. * The nature of intolerance or why oral sumatriptan cannot be used must be specified. Duration of Approval 5 years Renewal requests for sumatriptan may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 217, record 127, corpus 2025-01-01; name match only, not an eligibility decision
1 brand, same coverage
Jamp Sumatriptan · DIN 02545365 Manufacturer: Jamp Pharma Corporation; listing date 2024-12-30 Health Canada: Marketed since 2024-11-01 · brand JAMP SUMATRIPTAN · ATC N02CC01 SUMATRIPTAN · form Tablet · route Oral · ingredients SUMATRIPTAN (SUMATRIPTAN SUCCINATE) 100 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp Sumatriptan: Formulary list price $9.9866/unit (unit not stated in source; not the patient's cost)

Ministry pays: $9.9866 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103414 · Verify on the e-Formulary ↗ (DIN 02545365)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02545365). DIN 02545365: Jamp Sumatriptan Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200006; group id 545; item number 1475; lccId None; manufacturer id JPC Source form: Tab; strength: 100mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $9.9866; ministry $9.9866 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02545365 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103414
Interchangeable products
Apo-Sumatriptan · DIN 02268396 · $9.9867 Co Sumatriptan · DIN 02257904 · $9.9867 Imitrex · DIN 01950614 · not recorded Mylan-Sumatriptan · DIN 02268922 · $9.9867 PMS-Sumatriptan · DIN 02256444 · $9.9867 Ratio-Sumatriptan · DIN 02271591 · $9.9867 Sandoz Sumatriptan · DIN 02263033 · $9.9867 Sumatriptan · DIN 02286548 · $9.9867 Sumatriptan · DIN 02546043 · $9.9867
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02545365
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Sumatriptan DF · DIN 02545314 · 100mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access criteria on record are for Brand(s): Imitrex; DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Almotriptan Brand(s): Axert DOSAGE FORM/ STRENGTH: 6 mg, 12.5mg tablet Naratriptan Brand(s): Amerge DOSAGE FORM/ STRENGTH: 1 mg, 2.5 mg tablet Rizatriptan Brand(s): Maxalt, Maxalt RPD DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer Sumatriptan Brand(s): Imitrex DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and where the following information is provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. Duration of Approval: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. 217 Sumatriptan Brand(s): Imitrex Injection DOSAGE FORM/ STRENGTH: 12 mg/mL subcutaneous injection Brand(s): Imitrex Nasal Spray DOSAGE FORM/ STRENGTH: 5 mg/dose and 20 mg/dose nasal spray For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and has documented intolerance* to an oral triptan. The following information must also be provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. * The nature of intolerance or why oral sumatriptan cannot be used must be specified. Duration of Approval 5 years Renewal requests for sumatriptan may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 217, record 127, corpus 2025-01-01; name match only, not an eligibility decision
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Sumatriptan DF · DIN 02545314 Manufacturer: Jamp Pharma Corporation; listing date 2025-01-31 Health Canada: Marketed since 2024-09-30 · brand JAMP SUMATRIPTAN DF · ATC N02CC01 SUMATRIPTAN · form Tablet · route Oral · ingredients SUMATRIPTAN (SUMATRIPTAN SUCCINATE) 100 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp Sumatriptan DF: Formulary list price $9.9866/unit (unit not stated in source; not the patient's cost)

Ministry pays: $9.9866 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103409 · Verify on the e-Formulary ↗ (DIN 02545314)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02545314). DIN 02545314: Jamp Sumatriptan DF Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200028; group id 545; item number 1476; lccId None; manufacturer id JPC Source form: Tab; strength: 100mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $9.9866; ministry $9.9866 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02545314 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103409
Interchangeable products
Imitrex DF · DIN 02212161 · $9.9866 Sumatriptan DF · DIN 02385589 · $9.9866 Teva-Sumatriptan DF · DIN 02286831 · $9.9866
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02545314
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mylan-Sumatriptan · DIN 02268922 · 100mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access criteria on record are for Brand(s): Imitrex; DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Almotriptan Brand(s): Axert DOSAGE FORM/ STRENGTH: 6 mg, 12.5mg tablet Naratriptan Brand(s): Amerge DOSAGE FORM/ STRENGTH: 1 mg, 2.5 mg tablet Rizatriptan Brand(s): Maxalt, Maxalt RPD DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer Sumatriptan Brand(s): Imitrex DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and where the following information is provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. Duration of Approval: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. 217 Sumatriptan Brand(s): Imitrex Injection DOSAGE FORM/ STRENGTH: 12 mg/mL subcutaneous injection Brand(s): Imitrex Nasal Spray DOSAGE FORM/ STRENGTH: 5 mg/dose and 20 mg/dose nasal spray For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and has documented intolerance* to an oral triptan. The following information must also be provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. * The nature of intolerance or why oral sumatriptan cannot be used must be specified. Duration of Approval 5 years Renewal requests for sumatriptan may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 217, record 127, corpus 2025-01-01; name match only, not an eligibility decision
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mylan-Sumatriptan · DIN 02268922 Manufacturer: Mylan Pharmaceuticals ULC; listing date 2007-06-06 Health Canada: Marketed since 2010-01-12 · brand MYLAN-SUMATRIPTAN · ATC N02CC01 SUMATRIPTAN · form Tablet · route Oral · ingredients SUMATRIPTAN (SUMATRIPTAN SUCCINATE) 100 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Mylan-Sumatriptan: Formulary list price $9.9867/unit (unit not stated in source; not the patient's cost)

Ministry pays: $9.9867 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75432 · Verify on the e-Formulary ↗ (DIN 02268922)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02268922). DIN 02268922: Mylan-Sumatriptan Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200006; group id 545; item number 1475; lccId None; manufacturer id MYL Source form: Tab; strength: 100mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $9.9867; ministry $9.9867 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02268922 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75432
Interchangeable products
Apo-Sumatriptan · DIN 02268396 · $9.9867 Co Sumatriptan · DIN 02257904 · $9.9867 Imitrex · DIN 01950614 · not recorded Jamp Sumatriptan · DIN 02545365 · $9.9866 PMS-Sumatriptan · DIN 02256444 · $9.9867 Ratio-Sumatriptan · DIN 02271591 · $9.9867 Sandoz Sumatriptan · DIN 02263033 · $9.9867 Sumatriptan · DIN 02286548 · $9.9867 Sumatriptan · DIN 02546043 · $9.9867
Shortage status: active shortage (reported 2026-07-20, estimated to end 2027-02-09, last updated 2026-09-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02268922
Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Sumatriptan · DIN 02256444 · 100mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access criteria on record are for Brand(s): Imitrex; DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Almotriptan Brand(s): Axert DOSAGE FORM/ STRENGTH: 6 mg, 12.5mg tablet Naratriptan Brand(s): Amerge DOSAGE FORM/ STRENGTH: 1 mg, 2.5 mg tablet Rizatriptan Brand(s): Maxalt, Maxalt RPD DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer Sumatriptan Brand(s): Imitrex DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and where the following information is provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. Duration of Approval: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. 217 Sumatriptan Brand(s): Imitrex Injection DOSAGE FORM/ STRENGTH: 12 mg/mL subcutaneous injection Brand(s): Imitrex Nasal Spray DOSAGE FORM/ STRENGTH: 5 mg/dose and 20 mg/dose nasal spray For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and has documented intolerance* to an oral triptan. The following information must also be provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. * The nature of intolerance or why oral sumatriptan cannot be used must be specified. Duration of Approval 5 years Renewal requests for sumatriptan may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 217, record 127, corpus 2025-01-01; name match only, not an eligibility decision
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMS-Sumatriptan · DIN 02256444 Manufacturer: Pharmascience Inc.; listing date 2007-06-06 Health Canada: Marketed since 2005-08-24 · brand PMS-SUMATRIPTAN · ATC N02CC01 SUMATRIPTAN · form Tablet · route Oral · ingredients SUMATRIPTAN (SUMATRIPTAN SUCCINATE) 100 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

PMS-Sumatriptan: Formulary list price $9.9867/unit (unit not stated in source; not the patient's cost)

Ministry pays: $9.9867 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74165 · Verify on the e-Formulary ↗ (DIN 02256444)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02256444). DIN 02256444: PMS-Sumatriptan Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200006; group id 545; item number 1475; lccId None; manufacturer id PMS Source form: Tab; strength: 100mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $9.9867; ministry $9.9867 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02256444 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74165
Interchangeable products
Apo-Sumatriptan · DIN 02268396 · $9.9867 Co Sumatriptan · DIN 02257904 · $9.9867 Imitrex · DIN 01950614 · not recorded Jamp Sumatriptan · DIN 02545365 · $9.9866 Mylan-Sumatriptan · DIN 02268922 · $9.9867 Ratio-Sumatriptan · DIN 02271591 · $9.9867 Sandoz Sumatriptan · DIN 02263033 · $9.9867 Sumatriptan · DIN 02286548 · $9.9867 Sumatriptan · DIN 02546043 · $9.9867
Shortage status: resolved shortage (ended 2020-06-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02256444
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sumatriptan · DIN 02286548 · 100mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access criteria on record are for Brand(s): Imitrex; DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Almotriptan Brand(s): Axert DOSAGE FORM/ STRENGTH: 6 mg, 12.5mg tablet Naratriptan Brand(s): Amerge DOSAGE FORM/ STRENGTH: 1 mg, 2.5 mg tablet Rizatriptan Brand(s): Maxalt, Maxalt RPD DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer Sumatriptan Brand(s): Imitrex DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and where the following information is provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. Duration of Approval: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. 217 Sumatriptan Brand(s): Imitrex Injection DOSAGE FORM/ STRENGTH: 12 mg/mL subcutaneous injection Brand(s): Imitrex Nasal Spray DOSAGE FORM/ STRENGTH: 5 mg/dose and 20 mg/dose nasal spray For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and has documented intolerance* to an oral triptan. The following information must also be provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. * The nature of intolerance or why oral sumatriptan cannot be used must be specified. Duration of Approval 5 years Renewal requests for sumatriptan may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 217, record 127, corpus 2025-01-01; name match only, not an eligibility decision
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Sumatriptan · DIN 02286548 Manufacturer: Sanis Health Inc.; listing date 2011-08-04 Health Canada: Marketed since 2010-04-05 · brand SUMATRIPTAN · ATC N02CC01 SUMATRIPTAN · form Tablet · route Oral · ingredients SUMATRIPTAN (SUMATRIPTAN SUCCINATE) 100 MG · company Sanis health inc · schedule Prescription
Check this DIN again · Health Canada product record

Sumatriptan: Formulary list price $9.9867/unit (unit not stated in source; not the patient's cost)

Ministry pays: $9.9867 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77199 · Verify on the e-Formulary ↗ (DIN 02286548)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02286548). DIN 02286548: Sumatriptan Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200006; group id 545; item number 1475; lccId None; manufacturer id SAI Source form: Tab; strength: 100mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $9.9867; ministry $9.9867 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02286548 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77199
Interchangeable products
Apo-Sumatriptan · DIN 02268396 · $9.9867 Co Sumatriptan · DIN 02257904 · $9.9867 Imitrex · DIN 01950614 · not recorded Jamp Sumatriptan · DIN 02545365 · $9.9866 Mylan-Sumatriptan · DIN 02268922 · $9.9867 PMS-Sumatriptan · DIN 02256444 · $9.9867 Ratio-Sumatriptan · DIN 02271591 · $9.9867 Sandoz Sumatriptan · DIN 02263033 · $9.9867 Sumatriptan · DIN 02546043 · $9.9867
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02286548
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sumatriptan · DIN 02546043 · 100mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access criteria on record are for Brand(s): Imitrex; DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Almotriptan Brand(s): Axert DOSAGE FORM/ STRENGTH: 6 mg, 12.5mg tablet Naratriptan Brand(s): Amerge DOSAGE FORM/ STRENGTH: 1 mg, 2.5 mg tablet Rizatriptan Brand(s): Maxalt, Maxalt RPD DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer Sumatriptan Brand(s): Imitrex DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and where the following information is provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. Duration of Approval: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. 217 Sumatriptan Brand(s): Imitrex Injection DOSAGE FORM/ STRENGTH: 12 mg/mL subcutaneous injection Brand(s): Imitrex Nasal Spray DOSAGE FORM/ STRENGTH: 5 mg/dose and 20 mg/dose nasal spray For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and has documented intolerance* to an oral triptan. The following information must also be provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. * The nature of intolerance or why oral sumatriptan cannot be used must be specified. Duration of Approval 5 years Renewal requests for sumatriptan may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 217, record 127, corpus 2025-01-01; name match only, not an eligibility decision
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Sumatriptan · DIN 02546043 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2024-05-31 Health Canada: Marketed since 2024-04-29 · brand SUMATRIPTAN · ATC N02CC01 SUMATRIPTAN · form Tablet · route Oral · ingredients SUMATRIPTAN (SUMATRIPTAN SUCCINATE) 100 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Sumatriptan: Formulary list price $9.9867/unit (unit not stated in source; not the patient's cost)

Ministry pays: $9.9867 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103477 · Verify on the e-Formulary ↗ (DIN 02546043)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02546043). DIN 02546043: Sumatriptan Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200006; group id 545; item number 1475; lccId None; manufacturer id SIV Source form: Tab; strength: 100mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $9.9867; ministry $9.9867 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02546043 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103477
Interchangeable products
Apo-Sumatriptan · DIN 02268396 · $9.9867 Co Sumatriptan · DIN 02257904 · $9.9867 Imitrex · DIN 01950614 · not recorded Jamp Sumatriptan · DIN 02545365 · $9.9866 Mylan-Sumatriptan · DIN 02268922 · $9.9867 PMS-Sumatriptan · DIN 02256444 · $9.9867 Ratio-Sumatriptan · DIN 02271591 · $9.9867 Sandoz Sumatriptan · DIN 02263033 · $9.9867 Sumatriptan · DIN 02286548 · $9.9867
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02546043
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sumatriptan DF · DIN 02385589 · 100mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access criteria on record are for Brand(s): Imitrex; DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Almotriptan Brand(s): Axert DOSAGE FORM/ STRENGTH: 6 mg, 12.5mg tablet Naratriptan Brand(s): Amerge DOSAGE FORM/ STRENGTH: 1 mg, 2.5 mg tablet Rizatriptan Brand(s): Maxalt, Maxalt RPD DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer Sumatriptan Brand(s): Imitrex DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and where the following information is provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. Duration of Approval: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. 217 Sumatriptan Brand(s): Imitrex Injection DOSAGE FORM/ STRENGTH: 12 mg/mL subcutaneous injection Brand(s): Imitrex Nasal Spray DOSAGE FORM/ STRENGTH: 5 mg/dose and 20 mg/dose nasal spray For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and has documented intolerance* to an oral triptan. The following information must also be provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. * The nature of intolerance or why oral sumatriptan cannot be used must be specified. Duration of Approval 5 years Renewal requests for sumatriptan may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 217, record 127, corpus 2025-01-01; name match only, not an eligibility decision
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Sumatriptan DF · DIN 02385589 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-06-30 Health Canada: Marketed since 2023-06-01 · brand SUMATRIPTAN DF · ATC N02CC01 SUMATRIPTAN · form Tablet · route Oral · ingredients SUMATRIPTAN (SUMATRIPTAN SUCCINATE) 100 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Sumatriptan DF: Formulary list price $9.9866/unit (unit not stated in source; not the patient's cost)

Ministry pays: $9.9866 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87119 · Verify on the e-Formulary ↗ (DIN 02385589)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02385589). DIN 02385589: Sumatriptan DF Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200028; group id 545; item number 1476; lccId None; manufacturer id SIV Source form: Tab; strength: 100mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $9.9866; ministry $9.9866 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02385589 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87119
Interchangeable products
Imitrex DF · DIN 02212161 · $9.9866 Jamp Sumatriptan DF · DIN 02545314 · $9.9866 Teva-Sumatriptan DF · DIN 02286831 · $9.9866
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02385589
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (28:92 Miscellaneous Central Nervous System Drugs) and how they are covered

Matched class: 28:92 Miscellaneous Central Nervous System Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: PIZOTYLINE Some products covered without a code (check the product listing): ATOMOXETINE HCL, PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE 28:92 Miscellaneous Central Nervous System Drugs

ALMOTRIPTAN

· 9 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 6.25mg, 12.5mg · Tab

ELETRIPTAN

· 16 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 20mg, 40mg · Tab

FROVATRIPTAN SUCCINATE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 2.5mg · Tab

NARATRIPTAN HYDROCHLORIDE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1mg, 2.5mg · Tab

RIZATRIPTAN

· 44 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 5mg, 10mg · Orally Disintegrating Tab, Tab

ZOLMITRIPTAN

· 21 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 2.5mg · Orally Disintegrating Tab, Tab

PIZOTYLINE

· 1 products · General benefit · strengths: 1mg · Tab

ATOMOXETINE HCL

· 59 products · Listed, not a benefit (5), General benefit (40), Off-Formulary Interchangeable, not an ODB benefit (14) · strengths: 10mg, 18mg, 25mg, 40mg, 60mg, 80mg, 100mg · Cap

PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE

· 28 products · General benefit (19), Off-Formulary Interchangeable, not an ODB benefit (7), Listed, not a benefit (2) · strengths: 0.25mg, 0.5mg, 1mg, 1.5mg · Tab

ACAMPROSATE CALCIUM

· 1 products · Limited Use, codes 531 · strengths: 333mg · DR Tab

ENTACAPONE

· 4 products · Limited Use, codes 367 · strengths: 200mg · Tab

DIMETHYL FUMARATE

· 18 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 120mg, 240mg · DR Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:92 and 1 more
Full class listing Related classes: 28:08 Analgesics, 28:10 Opiate Antagonists, 28:12 Anticonvulsants, 28:16 Psychotherapeutic Agents, 28:20 C.N.S. Stimulants, 28:24 Sedatives and Hypnotics, 28:36 Antiparkinsonian Agents Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: migraine attacks with or without aura
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. ALMOTRIPTAN · Off-Formulary Interchangeable, not an ODB benefit INDICATIONS AND CLINICAL USE Adults (> 18 years of age) MYLAN-ALMOTRIPTAN (almotriptan malate) tablets are indicated for the acute treatment of migraine attacks with or without aura. PM: https://pdf.hres.ca/dpd_pm/00035358.PDF; date June 15, 2016; DIN 02398435; fetched 2026-09-10 Product monograph FROVATRIPTAN SUCCINATE · Off-Formulary Interchangeable, not an ODB benefit 1 INDICATIONS FROVA (frovatriptan tablets) is indicated for the acute treatment of migraine attacks with or without aura in adults. PM: https://pdf.hres.ca/dpd_pm/00084598.PDF; date SEP 03, 2004; DIN 02257084; fetched 2026-09-10 Product monograph NARATRIPTAN HYDROCHLORIDE · Off-Formulary Interchangeable, not an ODB benefit INDICATIONS AND CLINICAL USE TEVA-NARATRIPTAN (naratriptan hydrochloride) Tablets are indicated for the acute treatment of migraine attacks with or without aura in adults. PM: https://pdf.hres.ca/dpd_pm/00038181.PDF; date February 7, 2017; DIN 02314290; fetched 2026-09-10 Product monograph ZOLMITRIPTAN · Off-Formulary Interchangeable, not an ODB benefit 1 INDICATIONS ZOMIG (zolmitriptan; tablets, orally disintegrating tablets, nasal spray) is indicated for: • the acute treatment of migraine attacks with or without aura, in adults. PM: https://pdf.hres.ca/dpd_pm/00078682.PDF; date Aug 24, 1998; DIN 02238660; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1. Indications IMITREX DF (sumatriptan succinate) and IMITREX (sumatriptan succinate/sumatriptan hemisulphate) are indicated for the acute treatment of migraine attacks with or without aura. IMITREX DF and IMITREX are not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic, basilar, or ophthalmoplegic migraine (see 2 Contraindications). Safety and efficacy have not been established for cluster headache, which is present in an older, predominantly male population. 1.1. Pediatrics Pediatrics (< 18 years of age): The safety and efficacy of IMITREX DF and IMITREX in pediatrics patients have not been established and their use in this age group is not recommended (See 7.1.3 Pediatrics). 1.2. Geriatrics Geriatrics (> 65 years of age): Experience of the use of IMITREX DF and IMITREX in patients aged over 65 years is limited. Therefore, the use of IMITREX DF and IMITREX in patients over 65 years is not recommended (See 7.1.4 Geriatrics). https://pdf.hres.ca/dpd_pm/00082699.PDF PM date: DEC 09, 2025 Source product: IMITREX DF - TAB 100MG; DIN 02212161; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Mylan-Sumatriptan · DIN 02268922 Shortage status: active shortage (reported 2026-07-20, estimated to end 2027-02-09, last updated 2026-09-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02268922

Check this DIN again

Prepare an Exceptional Access request

SADIE has its own form for many drugs; this checklist prepares the answers; the ministry decides. Open SADIE

Use this text in SADIE’s free-text fields or read from it on a Telephone Request Service call. Review marks do not indicate eligibility. Evidence stays in this page until you copy it; nothing entered here is sent or saved. Do not enter patient identifiers.

EAP Telephone Request Service: The TRS can be accessed by calling toll-free at 1-866-811-9893 or 416-327-8109 (Toronto area) between 8:30 a.m. and 5:00 p.m. Monday through Friday (except holidays) and selecting the TRS option. Source; updated September 15, 2026

EAP fax: In Ontario: 1-866-811-9908 or 416-327-7526 (Toronto area). Outside Ontario: 1-833-905-4260. Source; updated September 15, 2026

Posted turnaround and Telephone Request Service scope
Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 15, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days |
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
Source; updated September 15, 2026

Sumatriptan (Imitrex)

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Prepare answers: For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and where the following information is provided:

Ministry criteria corpus 2025-01-01; page 217

Almotriptan Brand(s): Axert DOSAGE FORM/ STRENGTH: 6 mg, 12.5mg tablet
Naratriptan Brand(s): Amerge DOSAGE FORM/ STRENGTH: 1 mg, 2.5 mg tablet
Rizatriptan Brand(s): Maxalt, Maxalt RPD DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer
Sumatriptan Brand(s): Imitrex DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet
For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and where the following information is provided:
• Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and
• The number of attacks, duration, and severity of migraines.
Duration of Approval: 5 years
Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use.
Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches.
217 Sumatriptan Brand(s): Imitrex Injection DOSAGE FORM/ STRENGTH: 12 mg/mL subcutaneous injection
Brand(s): Imitrex Nasal Spray DOSAGE FORM/ STRENGTH: 5 mg/dose and 20 mg/dose nasal spray
For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and has documented intolerance* to an oral triptan. The following information must also be provided:
• Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and
• The number of attacks, duration, and severity of migraines.
* The nature of intolerance or why oral sumatriptan cannot be used must be specified.
Duration of Approval 5 years
Renewal requests for sumatriptan may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use.
Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches.

Prepared from the ministry's published criteria; eligibility is decided by the Exceptional Access Program.

Other review policies

For Imitrex, Taro-Sumatriptan, Jamp Sumatriptan DF, Mylan-Sumatriptan, PMS-Sumatriptan, Teva-Sumatriptan DF, Apo-Sumatriptan, Jamp Sumatriptan, Sumatriptan, Sumatriptan DF, Imitrex DF: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026